Author:
Blagden Sarah P., ,Billingham Lucinda,Brown Louise C.,Buckland Sean W.,Cooper Alison M.,Ellis Stephanie,Fisher Wendy,Hughes Helen,Keatley Debbie A.,Maignen Francois M.,Morozov Alex,Navaie Will,Pearson Sarah,Shaaban Abeer,Wydenbach Kirsty,Kearns Pamela R.
Abstract
AbstractThe traditional cancer drug development pathway is increasingly being superseded by trials that address multiple clinical questions. These are collectively termed Complex Innovative Design (CID) trials. CID trials not only assess the safety and toxicity of novel anticancer medicines but also their efficacy in biomarker-selected patients, specific cancer cohorts or in combination with other agents. They can be adapted to include new cohorts and test additional agents within a single protocol. Whilst CID trials can speed up the traditional route to drug licencing, they can be challenging to design, conduct and interpret. The Experimental Cancer Medicine Centres (ECMC) network, funded by the National Institute for Health Research (NIHR), Cancer Research UK (CRUK) and the Health Boards of Wales, Northern Ireland and Scotland, formed a working group with relevant stakeholders from clinical trials units, the pharmaceutical industry, funding bodies, regulators and patients to identify the main challenges of CID trials. The working group generated ten consensus recommendations. These aim to improve the conduct, quality and acceptability of oncology CID trials in clinical research and, importantly, to expedite the process by which effective treatments can reach cancer patients.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. International Agency for Research on Cancer. All cancers fact sheet. Globocan, 2018. http://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf (2018).
2. International Agency for Research on Cancer. Cancer tomorrow—Estimated number of incident cases from 2018 to 2040, all cancers, both sexes, all ages. https://gco.iarc.fr/tomorrow/graphic-isotype?type=0&;population=900&mode=population&sex=0&cancer=39&age_group=value&apc_male=0&apc_female=0 (2018).
3. The Institute of Cancer Research. From Patent to Patient—Analysing access to innovative cancer drugs. https://d1ijoxngr27nfi.cloudfront.net/docs/default-source/default-document-library/from-patent-to-patient.pdf?sfvrsn=8fa95f69_2 (2018).
4. Bhatt, D. L. & Mehta C. Adaptive designs for clinical trials. https://doi.org/10.1056/NEJMra1510061. https://www.nejm.org/doi/10.1056/NEJMra1510061 (2016).
5. Renfro, L. A. & Mandrekar, S. J. Definitions and statistical properties of master protocols for personalized medicine in oncology. J. Biopharm. Stat. 28, 217–228 (2018).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献